Prediction for TNF Inhibitor Users in RA Patients According to Reimbursement Criteria Based on DAS28
Author(s) -
Soyoung Won,
YoonKyoung Sung,
SooKyung Cho,
ChanBum Choi,
EunMi Koh,
SeongKyu Kim,
Jinseok Kim,
TaeHwan Kim,
HyounAh Kim,
Seong-Su Nah,
SoYoung Bang,
ChangHee Suh,
Seung Cheol Shim,
DaeHyun Yoo,
Bo Young Yoon,
SangHoon Lee,
Sung Won Lee,
ShinSeok Lee,
Yeon-Ah Lee,
Jaejoon Lee,
Jisoo Lee,
HyeSoon Lee,
Mi Kyoung Lim,
JaeBum Jun,
Chan Hong Jeon,
Young Ok Jung,
Won Tae Chung,
HoonSuk Cha,
JungYoon Choe,
SeungJae Hong,
SangCheol Bae
Publication year - 2014
Publication title -
journal of rheumatic diseases
Language(s) - English
Resource type - Journals
eISSN - 2093-940X
pISSN - 2233-4718
DOI - 10.4078/jrd.2014.21.2.64
Subject(s) - medicine , rheumatoid arthritis , reimbursement , infliximab , guideline , tnf inhibitor , physical therapy , etanercept , disease , pathology , health care , economics , economic growth
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom